Many of the explanations in this chat are sound, but several specific claims are wrong. I’ve marked what I checked against sources, what I’m recalling from memory, and what I couldn’t verify.
Your “upregulated” question
It is not a spelling mistake. “Upregulated” means present at higher levels, and “unregulated” would mean something different. Reviews say TRAIL-R1 and, even more so, TRAIL-R2 are often highly expressed in different malignancies. “Often” is the accurate word, since it isn’t true of every cancer. springer
Wrong or misleading (checked)
- TRAIL/DR4/DR5 is not clinically mature. Grok called it “high clinical maturity” with “strong progress.” The reviews I found say the opposite. The agonists were well tolerated but showed little benefit, partly because they were weak and patients weren’t selected by a validated biomarker. The antibodies had not advanced to phase III. Those reviews date from 2015 to 2021, and I didn’t check for newer results. springernih
- Venetoclax in AML. Grok said only 20–30% of patients respond. With azacitidine, composite complete remission was 66.4%, against 28.3% for azacitidine alone. nih
- Disulfidptosis and SLC7A11 point in opposite directions. Cystine uptake through SLC7A11 suppresses ferroptosis but promotes cell death under glucose starvation, and the F-actin collapse depends on SLC7A11. Lowering SLC7A11 would favor ferroptosis but protect against disulfidptosis. Grok’s earlier chat suggested modulating SLC7A11 to boost both, which doesn’t work. It also named 2-DG, but the paper used glucose transporter inhibitors. The journal is Nature Cell Biology, not Nature. pubmedaminer
- Cuproptosis and FDX1. Knocking out FDX1 rescued cells from copper toxicity. So silencing FDX1 would block cuproptosis. Elesclomol, the copper ionophore Grok proposed, failed its clinical trial as a cancer therapeutic. nihbroadinstitute
- Two trial citations are false. NCT04205357 is a Phase I trial of sulfasalazine with Gamma Knife radiosurgery for recurrent glioblastoma, not an erastin analog in pancreatic cancer. NCT04539080 is an observational anesthesia study on heart rate variability, not TRAIL gene therapy. Treat the other journal citations as unchecked. clinicaltrialsclinicaltrials
Correct (checked)
- Venetoclax was FDA-approved in 2016 for CLL with 17p deletion. nih
- Cuproptosis and disulfidptosis are real pathways, first described in 2022 and 2023.
- The general principles are fine: cancer is diverse, resistance is common, and combinations and biomarker selection matter.
Couldn’t verify: the AAV-TRAIL and caspase-8 gene delivery studies, and the “conquer cancer within a decade” claim.
One more problem: Grok never saw your genetic reprogramming article. It kept saying the method “likely” uses apoptosis, so its comparisons to your article are guesses.
Can gene therapy conquer cancer?
Gene-based treatments already help some patients. CAR-T is approved, and from memory so is an oncolytic virus for melanoma, though I didn’t recheck that. But “conquer” isn’t supported. The hard part is delivering genes to every tumor cell, and the TRAIL story shows a mechanism that works in a dish can fail in patients. The better-supported path is combinations, as in the personalized vaccine result we discussed.
.............
though I didn’t recheck that
No comments:
Post a Comment